Latest News
Ken Griffin’s multi-strategy hedge fund major Citadel has appointed AJ Bolduc, formerly of Goldman Sachs, to head Asia trading and equity capital markets within its International Equities team in Hong Kong, according to a report by Bloomberg.
Singapore sovereign wealth fund GIC has redeemed around $250m from Jain Global, less than two years after backing one of the hedge fund industry’s largest-ever launches, according to a report by The Business Time citing sources familiar with the matter.
Hedge funds significantly increased bearish bets against Hims & Hers Health in January, just weeks before the online healthcare provider became embroiled in a legal and regulatory dispute with Novo Nordisk, according to a report by Reuters citing data from Hazeltree.
SGX FX has announced a strategic integration with CME Group’s EBS Market and FX Spot+ platform, aiming to deliver enhanced connectivity, liquidity, and execution options for global forex market participants.
Tycho Capital has launched a new UCITS vehicle in partnership with London-based CapeView Capital, the Tycho CapeView European Long Short Fund, which debuted with over $40m in investor commitment and is targeting European equity long-short strategies.
Leading hedge funds, including Point72, King Street Capital, Millennium and Schonfeld, are establishing standalone private credit businesses as investor appetite for the fast-growing asset class continues to surge, according to a report by Financial News London.
Global hedge fund portfolios showed signs of heightened volatility in January amid ongoing geopolitical tensions, major policy shifts, and energy market swings, according to the latest Crowdedness Report from Hazeltree.
Hedge funds are entering 2026 with strong momentum after delivering double-digit returns last year and exceeding allocator expectations, according to a new survey by Goldman Sachs of pension funds, family offices, funds of funds, and other pools of capital.
Most life sciences and biopharma hedge funds started 2026 on the back foot, giving up ground in January after one of the strongest years on record for the sector with the pull-back coming despite a 2.5% gain in the Nasdaq Biotechnology Index, according to a report buy Institutional Investor.
Citadel has raised $1.25bn through a two-part US bond offering, conducted by Citadel Finance LLC, which included a three-year and a five-year fixed-rate note, with proceeds earmarked for debt repayment and potentially general corporate purposes, according to a report by Bloomberg.
